



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/612,391 Confirmation No. : 3207
Applicant : HARMUT KUEPPERS, et al.
Filed : July 3, 2003
TC/A.U. : 1614
Examiner : To Be Assigned
Docket No. : 029300.52512US
Customer No. : 23911
Title : USE OF AT1 RECEPTOR ANTAGONISTS FOR
PREVENTION OF SUBSEQUENT STROKES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and International Search Report, which the Examiner may deem relevant to patentability of the claims of the above-identified application.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be

Application No. 10/612,391
Information Disclosure Statement

appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

April 6, 2004




J. D. Evans

Registration No. 26,269

CROWELL & MORING, LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844

JDE/ms



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 3			Complete if Known	
			Application Number	10/612,391
			Filing Date	July 3, 2003
			First Named Inventor	Harmut KUEPPERS et al.
			Art Unit	1614
			Examiner Name	To be assigned
			Attorney Docket Number	029300.52512US

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				


FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	AA	WO-97/49394-A2	12-31-1997	NOVARTIS AG		AB
	AB	WO-01/15673-A2	03-08-2001	AVENTIS PHARMA DEUTSCHLAND GMBH		AB
	AC	WO-01/01987-A1	01-11-2001	ASTRAZENECA AB		AB
	AD	WO-99/45779	09-16-1999	SMITHKLINE BEECHAM CORPORATION		AB
	AE	WO-99/00383	01-07-1999	SMITHKLINE BEECHAM CORPORATION		AB
	AF	WO-97/36874	10-09-1997	SMITHKLINE BEECHAM CORPORATION		AB

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	AG	SCHRADER, JOACHIM, et al., Preventing Stroke: High Risk Patients Should Receive Ramipril Irrespective of Their Blood Pressure, BMJ, Vol. 324, March 23, 2002, pp 687-689.
	AH	SCHRADER, J. et al., Unerwünschte Arzneimittelwirkungen und Wechselwirkungen von AT ₁ -Rezeptorantagonisten, Medizinischen Hochschule Hannover, pp 141-168.
	AI	SCHRADER, J. Et al., Die Syst-Eur-Studie: Nutzeffekt der Therapie der isolierten systolischen Hypertonie bei älteren Patienten, Münch. Med. Wschr. 139, 1997, Nr. 7, MMV Medizin Verlag GmbH München, Germany, pp 693/35-696/38.
	AJ	KOLLMANN, K., et al., Initiales Blutdruckverhalten von Patienten mit acuter zerebraler Ischämie; Extended Abstracts, pp 573-574.
	AK	SCHRADER, JOACHIM, Wenn nachts der Blutdruck nicht abfällt: Schlaganfall-Risiko massiv erhöht, MMW-Fortschr. Med, 2002, pp 55-56, Nr. 7.
	AL	KIRCHBERG, A. et al., Antihypertensive Therapie mit Kalziumantagonisten und ACE-Hemmern bei Patienten nach zerebraler Ischämie, Nieren- und Hochdruckkrankheiten, Jahrgang 25, 1996, pp 385-387, Nr. 8.
	AM	LUEDERS, S., et al., Je höher desto früher: Hochdruck macht dement, MMW-Fortschr. Med, 2000, pp 42-44, Nr. 12.

Substitute for form 1449A/PTO	Complete if Known
-------------------------------	--------------------------



INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/612,391
			Filing Date	July 3, 2003
			First Named Inventor	Harmut KUEPPERS et al.
			Art Unit	1614
			Examiner Name	To be assigned
			Attorney Docket Number	029300.52512US
Sheet	2	of	3	
NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	AN	WITTE, M., et al., Antihypertensive Therapie mit ACE-Hemmern bei renoparenchymatöser Hypertonie mit und ohne nächtlichen Blutdruckabfall, Extended Abstracts, pp 580-581.		
	AO	SCHRADER, J., et al., Antihypertensive Therapie bei älteren Patienten, Münch. Med. Wschr. 138, 1996, pp 743/43-748/50.		
	AP	SCHRADER, J., et al., Antihypertensive Therapie bei älteren Patienten, Gustav Fischer Verlag Jena Z ärztl Fortbild (ZaeF), 1995, pp 825-832, Vol. 89.		
	AQ	BLÖMER, A., et al., Vergleichende Untersuchung der 24-Stunden-Blutdruckwirksamkeit der ACE-Hemmer Ramipril und Captopril bei Patienten mit essentieller Hypertonie; Nieren- und Hochdruckkrankheiten, Jahrgang 25, 1996, pp 392-394, Nr. 8.		
	AR	SCHRADER, J. et al., Bedeutung der 24-Stunden-Blutdruckmessung in der Diagnostik und Therapie der arteriellen Hypertonie, Klin Wochenschr, (1990), pp 1119-1126, Nr. 68.		
	AS	SCHRADER, J. Et al., Blutdrucksenkung – so verhindern Sie vier von zehn Schlaganfällen: Antihypertensive Therapie vollständig ausreizen, MMW-Fortschr. Med., 2000, pp 22-25, Nr. 1-2.		
	AT	SCHILLING, H. Et al., Was ist gesichert in der Therapie mit Konversionshemmern, Internist, 1987, pp 810-817, Nr. 28.		
	AU	LÜDERS, S. et al., Führt der Einsatz der Langzeitblutdruckmessung zu einer Reduzierten Anzahl von Antihypertensiva in einer Langzeitstudie? Prospektive, Randomisiert 5-Jahres-Studie zum Vergleich von Prazis- und 24-Stunden-Blutdruckmessung bei hypertenikern, J Hyperton, 2001, pp 7-15, Nr. 1.		
	AV	LÜDERS, S. et al., Praxisblutdruckmessung versus Langzeitblutdruckmessung unter der Therapie mit Ramipril: Erste Ergebnisse einer Langzeitstudie, Nieren- und Hochdruckkrankheiten, Jahrgang 25, 1995, pp 118-120, Nr. 3.		
	AW	LÜDERS, S. et al., Kombinationstherapie von β -Blockern und ACE-Hemmern bei essentieller Hypertonie, Nieren- und Hochdruckkrankheiten, Jahrgang 21, 1992, pp 677-679, Nr. 11.		
	AX	SCHRADER, J. et al., Zur einundzwanzigsten Folge: Hypertonie und Schlaganfall – ein risikoreiches Duo, MMW-Fortschr. Med., 2001, pp 1-12, Nr. 31-32.		
	AY	SCHRADER, JOACHIM et al., Akutphase des Schlaganfalls: Bluthochdruck senken oder nicht senken, MMW-Fortschr. Med., 2003, pp 41-42, Nr. 1-2.		
	AZ	SCHRADER, JOACHIM et al., Bei arterieller Hypertonie: ACE-Hemmer und Kombinationstherapie, Pharm. Unserer Zeit 32, 2003, pp 46-52, Nr. 1.		
	BA	KULSCHEWSKI, A. Et al., ACCESS-Studie: Blutdruckkontrolle mit Candesartan Cilexetil bei Patienten mit akuter zerebraler Ischämie und Hypertonie, Nieren- und Hochdruckkrankheiten, Jahrgang 29, 2000, pp 618-619, Nr. 12.		
	BB	SCHRADER, J. et al., Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR Study): A Randomised, Prospective long-term study to evaluate the Benefits of ABPM in patients on Antihypertensive Treatment, Journal of Human Hypertension, 2000, pp 435-440, Nr. 14.		
	BC	FLASNOECKER, MONIKA, Interview: Dient Blutdrucksenkung auch der Prävention des Schlaganfalls, Fortschritte der Medizin 115, 1997, pp 49-50, Nr. 5.		
	BD	SCHRADER, J. et al., Hypertension and Stroke – Rational Behind the ACCESS Trial, Basic Res. Cardiol 93: Supp. 2, 1998, pp 69-78.		
	BE	BOSCH, JACKIE, et al., Use of Ramipril in Preventing Stroke: Double Blind randomized Trial, BMJ, Vol. 324, March 23, 2002, pp 699-702.		
Substitute for form 1449A/PTO INFORMATION DISCLOSURE			Complete if Known	
			Application Number	10/612,391
			Filing Date	July 3, 2003
			First Named Inventor	Harmut KUEPPERS et al.



STATEMENT BY APPLICANT				Art Unit	1614
				Examiner Name	To be assigned
Sheet	3	of	3	Attorney Docket Number	029300.52512US
NON PATENT LITERATURE DOCUMENTS					
	BF	Hypertonie: PRO und KONTRA Fixe Kombinationstherapie, Fortschritte der Medizin 116, 1998, pp 37-38, Nr. 14.			
	BG	SCHRADER, J. et al., ACE-Hemmer, Internist, 1992, pp 356-360, Nr. 33.			
	BH	SCHRADER, JOACHIM. et al., The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors, Stroke, July 2003, pp 1699-1703.			
	BI	SCHRADER, J., Interview mit Studienleiter Prof. Joachim Schrader: Arbeitsplats-Hypertoniker gibt es deutlich mehr als erwartet			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.